Potential value of soluble APP alpha and APP beta in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives

被引:2
作者
Araki, Wataru [1 ]
Araki, Yumiko M. [3 ]
Mizusawa, Hidehiro [2 ]
机构
[1] Natl Ctr Neurol & Psychiat, Dept Demyelinating Dis & Aging, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Tokyo, Japan
[3] Juntendo Univ, Grad Sch Med, Dept Psychiat & Behav Sci, Tokyo, Japan
来源
NEUROLOGY AND CLINICAL NEUROSCIENCE | 2018年 / 6卷 / 04期
关键词
Alzheimer's disease; cerebrospinal fluid; dementia; mild cognitive impairment; soluble amyloid precursor protein; tau;
D O I
10.1111/ncn3.12195
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The significance of fluid biomarkers in the clinical evaluation of dementia disorders has been established. Among such biomarkers, tau (phosphorylated tau and total tau) and amyloid beta-protein 42 (A42) in the cerebrospinal fluid (CSF) stand out as relatively reliable biomarkers of Alzheimer-type dementia and are now included in recently announced diagnostic guidelines. However, these biomarkers still have some limitations, including variability issues; thus, additional biomarkers would benefit earlier diagnosis of dementia disorders. The CSF soluble amyloid precursor proteins, sAPP alpha and sAPP beta-direct metabolites of APP produced by alpha-secretase- and beta-secretase-mediated cleavageare potential biomarker candidates. However, there have been conflicting reports on their usefulness as diagnostic biomarkers. In this mini review, we consider recent biomarker studies on sAPPs with a special reference to their relevance to the neuropathology of Alzheimer's disease. We also discuss unresolved issues, such as those relating to methodology, and provide perspectives for future research.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 46 条
  • [1] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    Albert, Marilyn S.
    DeKosky, Steven T.
    Dickson, Dennis
    Dubois, Bruno
    Feldman, Howard H.
    Fox, Nick C.
    Gamst, Anthony
    Holtzman, David M.
    Jagust, William J.
    Petersen, Ronald C.
    Snyder, Peter J.
    Carrillo, Maria C.
    Thies, Bill
    Phelps, Creighton H.
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (03) : 270 - 279
  • [2] Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
    Alcolea, Daniel
    Martinez-Lage, Pablo
    Sanchez-Juan, Pascual
    Olazaran, Javier
    Antunez, Carmen
    Izagirre, Andrea
    Ecay-Torres, Mirian
    Estanga, Ainara
    Clerigue, Montserrat
    Concepcion Guisasola, Maria
    Sanchez Ruiz, Domingo
    Marin Munoz, Juan
    Calero, Miguel
    Blesa, Rafael
    Clarimon, Jordi
    Carmona-Iragui, Maria
    Morenas-Rodriguez, Estrella
    Rodriguez-Rodriguez, Eloy
    Vazquez Higuera, Jose Luis
    Fortea, Juan
    Lleo, Alberto
    [J]. NEUROLOGY, 2015, 85 (07) : 626 - 633
  • [3] Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
    Alcolea, Daniel
    Carmona-Iragui, Maria
    Suarez-Calvet, Marc
    Belen Sanchez-Saudinos, M.
    Sala, Isabel
    Anton-Aguirre, Sofia
    Blesa, Rafael
    Clarimon, Jordi
    Fortea, Juan
    Lleo, Alberto
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (01) : 157 - 167
  • [4] Amyloid Cascade and Tau Pathology Cerebrospinal Fluid Markers in Mild Cognitive Impairment with regards to Alzheimer's Disease Cerebral Metabolic Signature
    Alexopoulos, Panagiotis
    Guo, Liang-Hao
    Jiang, Meizi
    Bujo, Hideaki
    Grimmer, Timo
    Foerster, Stefan
    Drzezga, Alexander
    Kurz, Alexander
    Perneczky, Robert
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2013, 36 (02) : 401 - 408
  • [5] Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid
    Alexopoulos, Panagiotis
    Tsolakidou, Amalia
    Roselli, Francesco
    Arnold, Anila
    Grimmer, Timo
    Westerteicher, Christine
    Leante, Maria Rosaria
    Foerstl, Hans
    Livrea, Paolo
    Kurz, Alexander
    Perneczky, Robert
    [J]. ALZHEIMERS & DEMENTIA, 2012, 8 (04) : 304 - 311
  • [6] Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders
    Araki, Wataru
    Hattori, Kotaro
    Kanemaru, Kazutomi
    Yokoi, Yuma
    Omachi, Yoshie
    Takano, Harumasa
    Sakata, Masuhiro
    Yoshida, Sumiko
    Tsukamoto, Tadashi
    Murata, Miho
    Saito, Yuko
    Kunugi, Hiroshi
    Goto, Yu-Ichi
    Nagaoka, Utako
    Nagao, Masahiro
    Komori, Takashi
    Arima, Kunimasa
    Ishii, Kenji
    Murayama, Shigeo
    Matsuda, Hiroshi
    Tachimori, Hisateru
    Araki, Yumiko M.
    Mizusawa, Hidehiro
    [J]. BIOMARKER RESEARCH, 2017, 5
  • [7] Post-translational regulation of the β-secretase BACE1
    Araki, Wataru
    [J]. BRAIN RESEARCH BULLETIN, 2016, 126 : 170 - 177
  • [8] Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
    Blennow, Kaj
    Dubois, Bruno
    Fagan, Anne M.
    Lewczuk, Piotr
    de Leon, Mony J.
    Hampel, Harald
    [J]. ALZHEIMERS & DEMENTIA, 2015, 11 (01) : 58 - 69
  • [9] Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease
    Brinkmalm, Gunnar
    Brinkmalm, Ann
    Bourgeois, Philippe
    Persson, Rita
    Hansson, Oskar
    Portelius, Erik
    Mercken, Marc
    Andreasson, Ulf
    Parent, Stephane
    Lipari, Francesco
    Ohrfelt, Annika
    Bjerke, Maria
    Minthon, Lennart
    Zetterberg, Henrik
    Blennow, Kaj
    Nutu, Magdalena
    [J]. BRAIN RESEARCH, 2013, 1513 : 117 - 126
  • [10] Constitutive secretion of tau protein by an unconventional mechanism
    Chai, Xiyun
    Dage, Jeffrey L.
    Citron, Martin
    [J]. NEUROBIOLOGY OF DISEASE, 2012, 48 (03) : 356 - 366